z-logo
open-access-imgOpen Access
Early access programs: Benefits, challenges, and key considerations for successful implementation
Author(s) -
Sanjaykumar L. Patil
Publication year - 2016
Publication title -
perspectives in clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 8
eISSN - 2229-5488
pISSN - 2229-3485
DOI - 10.4103/2229-3485.173779
Subject(s) - commercialization , key (lock) , white paper , expanded access , business , process management , medicine , political science , computer science , computer security , marketing , oncology , law
Early access programs, (EAPs) are adopted by an increasing number of pharma companies due to several benefits offered by these programs. EAPs offer ethical, compliant, and controlled mechanisms of access to investigational drugs outside of the clinical trial space and before the commercial launch of the drug, to patients with life-threatening diseases having no treatment options available. In addition to the development of positive relationships with key opinion leaders (KOL), patients, advocacy groups and regulators, the data captured from the implementation of EAPs supports in the formulation of global commercialization strategies. This white paper outlines various circumstances to be considered for the implementation of EAPs named patient programs, the regulatory landscape, the benefits and challenges associated with implementing these programs and the key considerations for their successful implementation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here